Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias

Cancer Genetics and Cytogenetics

Volumn 169, Issue 2, 2006, Pages 128-137

  Yoshimoto, Maisa ^a   Cutz, Jean Claude ^a,b   Nuin, Paulo A S ^a   Joshua, Anthony M ^a,c   Bayani, Jane ^a   Evans, Andrew J ^a,c   Zielenska, Maria ^c,d   Squire, Jeremy A ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CANCER TISSUE; CARCINOMA IN SITU; CENTROMERE; CHROMOSOME 10; CONTROLLED STUDY; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE LOCUS; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERPHASE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA IN SITU; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN EXPRESSION;

GENE DELETION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; MALE; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE;

EID: 33747842237     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.04.003     Document Type: Article

References (66)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., Feuer E.J., and Thun M.J. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
2. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 2000. CA Cancer J Clin 50 (2000) 7-33
3. Gronberg H. Prostate cancer epidemiology. Lancet 361 (2003) 859-864
4. DeMarzo A.M., Nelson W.G., Isaacs W.B., and Epstein J.I. Pathological and molecular aspects of prostate cancer. Lancet 361 (2003) 955-964
5. Dreher T., Zentgraf H., Abel U., Kappeler A., Michel M.S., Bleyl U., and Grobholz R. Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch 444 (2004) 509-517
6. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J., and Kallioniemi O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9 (1995) 401-406
7. Elo J.P., and Visakorpi T. Molecular genetics of prostate cancer. Ann Med 33 (2001) 130-141
8. Verhagen P.C., Zhu X.L., Rohr L.R., Cannon-Albright L.A., Tavtigian S.V., Skolnick M.H., and Brothman A.R. Microdissection, DOP-PCR, and comparative genomic hybridization of paraffin-embedded familial prostate cancers. Cancer Genet Cytogenet 122 (2000) 43-48
9. Qian J., Jenkins R.B., and Bostwick D.G. Determination of gene and chromosome dosage in prostatic intraepithelial neoplasia and carcinoma. Anal Quant Cytol Histol 20 (1998) 373-380
10. Zitzelsberger H., Engert D., Walch A., Kulka U., Aubele M., Hofler H., Bauchinger M., and Werner M. Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer 84 (2001) 202-208
11. Wolf M., Mousses S., Hautaniemi S., Karhu R., Huusko P., Allinen M., Elkahloun A., Monni O., Chen Y., Kallioniemi A., and Kallioniemi O.P. High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression. Neoplasia 6 (2004) 240-247
12. Kasahara K., Taguchi T., Yamasaki I., Kamada M., Yuri K., and Shuin T. Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization. Cancer Genet Cytogenet 137 (2002) 59-63
13. van Dekken H., Paris P.L., Albertson D.G., Alers J.C., Andaya A., Kowbel D., van der Kwast T.H., Pinkel D., Schroder F.H., Vissers K.J., Wildhagen M.F., and Collins C. Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis. Genes Chromosomes Cancer 39 (2004) 249-256
14. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., and Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
15. Whang Y.E., Wu X., Suzuki H., Reiter R.E., Tran C., Vessella R.L., Said J.W., Isaacs W.B., and Sawyers C.L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 95 (1998) 5246-5250
16. Besson A., Robbins S.M., and Yong V.W. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem 263 (1999) 605-611
17. Ramaswamy S., Nakamura N., Vazquez F., Batt D.B., Perera S., Roberts T.M., and Sellers W.R. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 96 (1999) 2110-2115
18. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 15 (2004) 171-176
19. Ohigashi T., Mizuno R., Nakashima J., Marumo K., and Murai M. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 62 (2005) 61-68
20. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22 (2004) 2954-2963
21. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
22. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
23. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., and Reed J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
24. Ashcroft M., Ludwig R.L., Woods D.B., Copeland T.D., Weber H.O., MacRae E.J., and Vousden K.H. Phosphorylation of HDM2 by Akt. Oncogene 21 (2002) 1955-1962
25. Graff J.R., Konicek B.W., McNulty A.M., Wang Z., Houck K., Allen S., Paul J.D., Hbaiu A., Goode R.G., Sandusky G.E., Vessella R.L., and Neubauer B.L. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275 (2000) 24500-24505
26. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., and Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
27. Richardson C.J., Broenstrup M., Fingar D.C., Julich K., Ballif B.A., Gygi S., and Blenis J. SKAR is a specific target of S6 kinase 1 in cell growth control. Curr Biol 14 (2004) 1540-1549
28. Stiles B., Groszer M., Wang S., Jiao J., and Wu H. PTENless means more. Dev Biol 273 (2004) 175-184
29. Porkka K.P., and Visakorpi T. Molecular mechanisms of prostate cancer. Eur Urol 45 (2004) 683-691
30. Di Cristofano A., Pesce B., Cordon-Cardo C., and Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat Genet 19 (1998) 348-355
31. Rennie P.S., and Nelson C.C. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev 17 (1998) 401-409
32. Dong J.T. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 20 (2001) 173-193
33. Visakorpi T. The molecular genetics of prostate cancer. Urology 62 (2003) 3-10
34. De Marzo A.M., DeWeese T.L., Platz E.A., Meeker A.K., Nakayama M., Epstein J.I., Isaacs W.B., and Nelson W.G. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 91 (2004) 459-477
35. Kwabi-Addo B., Giri D., Schmidt K., Podsypanina K., Parsons R., Greenberg N., and Ittmann M. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A 98 (2001) 11563-11568
36. Korshunov A., Sycheva R., Gorelyshev S., and Golanov A. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol 18 (2005) 1258-1263
37. Kawai T., Hiroi S., Nakanishi K., Sakurai Y., and Torikata C. Abnormalities in chromosome 17 and p53 in lung carcinoma cells detected by fluorescence in situ hybridization. Pathol Int 54 (2004) 413-419
38. Mezzelani A., Alasio L., Bartoli C., Bonora M.G., Pierotti M.A., Rilke F., and Pilotti S. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 80 (1999) 519-525
39. Al-Maghrabi J., Vorobyova L., Chapman W., Jewett M., Zielenska M., and Squire J.A. p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens. Mod Pathol 14 (2001) 1252-1262
40. Verhagen P., van Duijn P., Hermans K., Looijenga L., van Gurp R., Stoop H., van der Kwast T., and Trapman J. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 208 (2006) 699-707
41. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., and Pandolfi P.P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27 (2001) 222-224
42. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Van Dyke T., Cordon-Cardo C., and Pandolfi P.P. Pten dose dictates cancer progression in the prostate. PLoS Biol 1 (2003) E59
43. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., Cordon-Cardo C., and Pandolfi P.P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 (2005) 725-730
44. Kotelevets L., van Hengel J., Bruyneel E., Mareel M., van Roy F., and Chastre E. Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness. FASEB J 19 (2005) 115-117
45. Koksal I.T., Dirice E., Yasar D., Sanlioglu A.D., Ciftcioglu A., Gulkesen K.H., Ozes N.O., Baykara M., Luleci G., and Sanlioglu S. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol 22 (2004) 307-312
46. McMenamin M.E., Soung P., Perera S., Kaplan I., Loda M., and Sellers W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59 (1999) 4291-4296
47. Majumder P.K., and Sellers W.R. Akt-regulated pathways in prostate cancer. Oncogene 24 (2005) 7465-7474
48. Chee K.G., Lara P.N., Longmate J., Twardowski P., Quinn D.I., Chatta G., and Gandara D.R. The AKT inhibitor perifosine in biochemically recurrent, hormone-sensitive prostate cancer (HSPC): A Phase II California Cancer Consortium Trial. Proc ASCO (2005) Abstract no. 4642
49. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., Loda M., Lane H.A., and Sellers W.R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 (2004) 594-601
50. Li X., Luwor R., Lu Y., Liang K., and Fan Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 25 (2005) 525-535
51. Tanaka M., Rosser C.J., and Grossman H.B. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. Cancer Detect Prev 29 (2005) 170-174
52. Wu L., Birle D.C., and Tannock I.F. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65 (2005) 2825-2831
53. Lin H.K., Hu Y.C., Lee D.K., and Chang C. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 18 (2004) 2409-2423
54. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., Jen J., Isaacs W.B., Bova G.S., and Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57 (1997) 4997-5000
55. Pesche S., Latil A., Muzeau F., Cussenot O., Fournier G., Longy M., Eng C., and Lidereau R. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 16 (1998) 2879-2883
56. Gray I.C., Stewart L.M., Phillips S.M., Hamilton J.A., Gray N.E., Watson G.J., Spurr N.K., and Snary D. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 78 (1998) 1296-1300
57. Feilotter H.E., Nagai M.A., Boag A.H., Eng C., and Mulligan L.M. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16 (1998) 1743-1748
58. Wang S.I., Parsons R., and Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 4 (1998) 811-815
59. Suzuki H., Freije D., Nusskern D.R., Okami K., Cairns P., Sidransky D., Isaacs W.B., and Bova G.S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58 (1998) 204-209
60. Dong J.T., Sipe T.W., Hyytinen E.R., Li C.L., Heise C., McClintock D.E., Grant C.D., Chung L.W., and Frierson Jr. H.F. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 17 (1998) 1979-1982
61. Orikasa K., Fukushige S., Hoshi S., Orikasa S., Kondo K., Miyoshi Y., Kubota Y., and Horii A. Infrequent genetic alterations of the PTEN gene in Japanese patients with sporadic prostate cancer. J Hum Genet 43 (1998) 228-230
62. Muller M., Rink K., Krause H., and Miller K. PTEN/MMAC1 mutations in prostate cancer. Prostate Cancer Prostatic Dis 3 (2000) S32
63. Dong J.T., Li C.L., Sipe T.W., and Frierson Jr. H.F. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res 7 (2001) 304-308
64. Halvorsen O.J., Haukaas S.A., and Akslen L.A. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 9 (2003) 1474-1479
65. Lieberfarb M.E., Lin M., Lechpammer M., Li C., Tanenbaum D.M., Febbo P.G., Wright R.L., Shim J., Kantoff P.W., Loda M., Meyerson M., and Sellers W.R. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res 63 (2003) 4781-4785
66. Fenic I., Franke F., Failing K., Steger K., and Woenckhaus J. Expression of PTEN in malignant and non-malignant human prostate tissues: comparison with p27 protein expression. J Pathol 203 (2004) 559-566